登录 | 注册    关注公众号  
微信公众号
搜索
 > 【IL-13】

IL-13信息

英文名称:Interleukin-13
中文名称:白细胞介素-13
靶点别称:Interleukin-13,IL13,Interleukin 13,IL-13,Bronchial Hyperresponsiveness-1 (Bronchial Asthma),Allergic Rhinitis,P600,NC30,MGC116789,MGC116788,BHR1,MGC116786,ALRH
上市药物数量:1
临床药物数量:6
最高研发阶段:批准上市

IL-13产品列表

ACRO质量管理体系
 
评论(3)
IL3-H52H4|Human IL-13 Protein, His Tag
  1. 156XXXXXXX1
  2. 1人赞
  3. 2月份购买了IL-3蛋白产品做开发实验的试用,本产品的表现超出预期,抗原和目标样品结合非常稳定,耐用性数据也非常漂亮,几轮实验后很快就拟定了实验参数,省时省力!后续会持续支持ACRO的产品
  4. 2023-03-15
IL3-C52H4|Canine IL-13 Protein, His Tag
  1. 138XXXXXXX9
  2. 1人赞
  3. 我们购买该产品用于做抗体筛选,用作检测试剂,可应用于Binding ELISA和细胞学实验,产品生物学活性好,并且特异性很高。
  4. 2022-11-23
IL3-H52H4|Human IL-13 Protein, His Tag
  1. 151XXXXXXX9
  2. 0人赞
  3. Human IL-13 Protein, His Tag(货号IL3-H52H4),我们用来做Binding ELISA的,评价自主研发的ADC药物与IL3靶点的一个结合能力,结果显示,曲线图谱表达还不错,同时该抗原的表现也比较特异,果然Acro家的抗体一如既往好用
  4. 2023-02-13
 

IL-13分子别名

IL13,ALRH,BHR1,MGC116786,MGC116788,MGC116789,P600,Interleukin-13

IL-13分子背景

Interleukin 13 (IL13) is also known as ALRH, BHR1and P600, is a single-chain glycosylated polypeptide, and is a cytokine critical in regulating inflammatory and immune responses. IL13 is secreted by many cell types, but especially by T helper type 2 (Th2) cells. IL-13 induces its effects through a multi-subunit receptor that includes the alpha chain of the IL-4 receptor (IL-4Rα) and at least one of two known IL-13-specific binding chains. The functions of IL-13 overlap considerably with those of IL-4, especially with regard to changes induced on hematopoietic cells, but these effects are probably less important given the more potent role of IL-4. IL-13 induces matrix metalloproteinases (MMPs) as part of a mechanism that protects against excessive allergic inflammation that predisposes to asphyxiation. IL-13 induces many features of allergic lung disease, including airway hyperresponsiveness, goblet cell metaplasia and mucus hypersecretion, which all contribute to airway obstruction.

IL-13上市药物信息

英文名称 中文名称 研发代码 研发阶段 公司 最早商品名 最早批准国家 最早适应症 最早批准公司 最早批准日期 适应症 临床试验
Tralokinumab BAK-502G9; CAT-354 批准上市 Medimmune Llc ADBRY, Adtralza EU 特应性皮炎 Leo Pharma Inc 2021-06-17 特发性肺纤维化, 哮喘, 溃疡性结肠炎, 特应性皮炎 详情

IL-13临床药物信息

英文名称 研发代码 研发阶段 公司 适应症 临床试验
Lebrikizumab RG-3637; TNX-650; Anti-IL-13; MILR-1444A; PRO-301444; RO-4909832; RO-5490255; DRM-06; R-3637 临床三期 基因泰克 特发性肺纤维化, 霍奇金病, 皮炎, 皮肤性疾病, 哮喘, 阿尔茨海默病, 慢性阻塞性肺疾病, 特应性皮炎, 湿疹, 遗传性皮肤病 详情
SAR-443726 SAR-443726 临床一期 赛诺菲 特应性皮炎 详情
Dectrekumab/VAK-694 QBX-258 临床二期 诺华制药 淋巴水肿, 哮喘 详情
SAR-443765 SAR-443765 临床一期 赛诺菲 哮喘, 炎性疾病 详情
PF-07264660 PF-07264660 临床一期 辉瑞 详情
Cendakimab RPC-4046; ABT-308; CC-93538 临床三期 Abbott Laboratories 嗜酸细胞性胃肠炎(EG), 嗜酸性粒细胞性食管炎, 哮喘, 特应性皮炎, 湿疹 详情

消息提示

请输入您的联系方式,再点击提交!

确定